Brief: Medigene Says Co, Iricor, Université De Montréal Sign Collaboration, Licensing Option On Novel Cancer Antigens
29/01/2020 23:07
Jan 29 (Reuters) - Medigene AG MDG1k.DE :
* MEDIGENE SAYS CO, IRICOR AND UNIVERSITÉ DE MONTRÉAL SIGN
COLLABORATION AND EXCLUSIVE LICENSING OPTION ON NOVEL CANCER
ANTIGENS
* UNDER TERMS OF AGREEMENT, MEDIGENE WILL EVALUATE A NUMBER
OF
PROPRIETARY TSA TARGETS PROVIDED BY UDEM THROUGH IRICOR
* CO WILL RECEIVE OPTION TO EXERCISE A LICENSE TO DEVELOP &
COMMERCIALIZE T CELL RECEPTORS AGAINST UP TO 5 OF NOVEL CANCER
ANTIGENS
Source text for Eikon: ID:nPex4rfjta
Further company coverage: MDG1k.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medigene AG
See all newsBrief: Medigene Files Application For The Opening Of Insolvency Proceedings
Brief: Medigene Files Patent For Unique Nk-Specific TCR Construct With European Patent Office
Brief: Medigene AG Says Co Amends Financial Guidance For 2024
Brief: Medigene AG Expands Protection Of KRAS Library With Filing Of New Patent Application
Brief: Medigene H1 Revenue EUR 4.5 Million